The aim of this retrospective study was to analyze objective responses, time to progression and overall survival of the patients with metastatic colorectal cancer treated with first-line systemic therapy in respect of KRAS and BRAF status. The gene discussed is KRAS; the disease is metastatic colorectal cancer.